» Articles » PMID: 38426161

Successful Pregnancy Using Oral DHEA Treatment for Hypoandrogenemia in a 30-year-old Female with 5 Recurrent Miscarriages, Including Fetal Demise at 24 Weeks: a Case Report

Overview
Specialty General Medicine
Date 2024 Mar 1
PMID 38426161
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoandrogenemia is not usually considered as a potential cause of recurrent miscarriage. We present the case of a 30-year-old female with 6 previous pregnancies resulting in one live birth and 5 pregnancy losses, including fetal demise at 24 weeks gestation. She had standard investigations after her 4th loss, at a specialized miscarriage clinic. Lupus anticoagulant, anticardiolipin antibodies, thyroid function, parental karyotypes were all normal. Fetal products confirmed triploidy for her 4th miscarriage at 16 weeks gestation. She was reassured and advised to conceive again but had fetal demise after 24 weeks gestation. This was her 5th pregnancy loss with no explanation. She attended our Restorative Reproductive Medicine (RRM) clinic in January 2022. In addition to poor follicle function, we found hypoandrogenemia for the first time. Treatment included follicle stimulation with clomiphene and DHEA 25 mg twice daily pre-conception with DHEA 20 mg once daily maintained throughout pregnancy. She delivered a healthy baby boy by cesarean section at 36 weeks gestation in November 2023. Hypoandrogenemia should be considered as a contributory factor for women with recurrent miscarriage or late pregnancy loss. Restoration of androgens to normal levels with oral DHEA is safe and can improve pregnancy outcome.

References
1.
Fouany M, Sharara F . Is there a role for DHEA supplementation in women with diminished ovarian reserve?. J Assist Reprod Genet. 2013; 30(9):1239-44. PMC: 3800538. DOI: 10.1007/s10815-013-0018-x. View

2.
. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. 2020; 113(3):533-535. DOI: 10.1016/j.fertnstert.2019.11.025. View

3.
Toljan K, Vrooman B . Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Med Sci (Basel). 2018; 6(4). PMC: 6313374. DOI: 10.3390/medsci6040082. View

4.
Duane M, Stanford J, Porucznik C, Vigil P . Fertility Awareness-Based Methods for Women's Health and Family Planning. Front Med (Lausanne). 2022; 9:858977. PMC: 9171018. DOI: 10.3389/fmed.2022.858977. View

5.
Eleje G, Ugwu E, Igbodike E, Malachy D, Nwankwo E, Ugboaja J . Prevalence and associated factors of recurrent pregnancy loss in Nigeria according to different national and international criteria (ASRM/ESHRE vs. WHO/RCOG). Front Reprod Health. 2023; 5:1049711. PMC: 9989171. DOI: 10.3389/frph.2023.1049711. View